Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 35, 2024 - Issue 1
Submit an article Journal homepage
850
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

Andreas Pintera Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, GermanyView further author information
,
Kilian Eyerichb Department of Dermatology and Venerology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany;c Karolinska Institutet and Karolinska University Hospital, Stockholm, SwedenView further author information
,
Antonio Costanzod Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy;e Dermatology, Humanitas Research Hospital IRCCS, Rozzano, Milan, ItalyView further author information
,
Alyssa Garreltsf Eli Lilly and Company, Indianapolis, Indiana, USAView further author information
,
Christopher Schusterf Eli Lilly and Company, Indianapolis, Indiana, USA;g Department of Dermatology, Medical University of Vienna, Vienna, AustriaView further author information
,
Can Merth HaaPACS GmbH, Schriesheim, GermanyView further author information
,
Anastasia Lampropoulouf Eli Lilly and Company, Indianapolis, Indiana, USAView further author information
,
Konstantinos Fotiouf Eli Lilly and Company, Indianapolis, Indiana, USAView further author information
,
Julia-Tatjana Mauli Department of Dermatology, University Hospital Zurich, Zurich, Switzerland;j Faculty of Medicine, University of Zürich, Zurich, SwitzerlandView further author information
&
Kim A. Pappk Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada;l Division of Dermatology, Department of Medicine, University of Toronto, Ontario, CanadaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9557-3642View further author information
ORCID Icon show all
Article: 2350227 | Received 29 Feb 2024, Accepted 24 Apr 2024, Published online: 26 May 2024

References

  • Pinter A, Puig L, Schäkel K, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):1–5. doi: 10.1111/jdv.18376.
  • Reich K, Augustin M, Thaçi D, et al. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Br J Dermatol. 2020;182(4):869–879. doi: 10.1111/bjd.18384.
  • Salame N, Ehsani-Chimeh N, Armstrong AW. Comparison of physical and mental functioning among moderate-to-severe psoriasis patients on biologic versus oral therapy. Arch Dermatol Res. 2019;311(6):453–460. doi: 10.1007/s00403-019-01918-9.
  • van den Reek JMPA, Seyger MMB, van Lümig PPM, et al. The journey of adult psoriasis patients towards biologics: past and present-results from the BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2018;32(4):615–623. doi: 10.1111/jdv.14684.
  • Seneschal J, Lacour J-P, Bewley A, et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol. 2020;34(11):2566–2573. doi: 10.1111/jdv.16568.
  • Scala E, Megna M, Amerio P, et al. Patients’ demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. PLoS One. 2020;15(8):e0237267. doi: 10.1371/journal.pone.0237267.
  • Maurelli M, Gisondi P, Girolomoni G. Tailored biological treatment for patients with moderate-to-severe psoriasis. Expert Rev Clin Immunol. 2023;19(1):37–43. doi: 10.1080/1744666X.2023.2141226.
  • Anandarajah A. Imaging in psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44(2):157–165. doi: 10.1007/s12016-012-8304-4.
  • Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70(12):2152–2154. doi: 10.1136/ard.2011.150938.
  • Schäkel K, Reich K, Asadullah K, et al. Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‘clinical super response’): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol. 2023;37(10):2016–2027. doi: 10.1111/jdv.19236.
  • Lynde C, Riedl E, Maul J-T, et al. Comparative effectiveness of biologics across subgroups of patients with moderate-to-Severe plaque psoriasis: results at week 12 from the PSoHO study in a Real-World setting. Adv Ther. 2023;40(3):869–886. doi: 10.1007/s12325-022-02379-9.
  • Zagar A, Kadziola Z, Lipkovich I, et al. Evaluating bias control strategies in observational studies using frequentist model averaging. J Biopharm Stat. 2022;32(2):247–276. doi: 10.1080/10543406.2021.1998095.
  • Hjort NL, Claeskens G. Frequentist model average estimators. J Am Stat Assoc. 2003;98(464):879–899. doi: 10.1198/016214503000000828.
  • van Lümig PPM, van de Kerkhof PCM, Boezeman JBM, et al. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients. J Eur Acad Dermatol Venereol. 2013;27(5):593–600. doi: 10.1111/j.1468-3083.2012.04496.x.
  • Torres T, Puig L, Vender R, et al. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567–579. doi: 10.1007/s40257-021-00598-4.
  • Lebwohl M, Iversen L, Eidsmo L, et al. Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies. Clin Exp Dermatol. 2023. doi: 10.1093/ced/llad329.
  • Nagy G, van Vollenhoven RF. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther. 2015;17(1):181. doi: 10.1186/s13075-015-0707-1.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.